Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

182.64 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
Via MarketMinute
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Why Axsome Therapeutics Stock Rocketed Higher to End 2025 ↗
Axsome Therapeutics shareholders got a New Year's gift from the FDA. 
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Axsome Advances Toward FDA Filing For Drug To Treat Narcolepsy ↗
AXS-12 is being developed to treat cataplexy in narcolepsy by targeting norepinephrine and dopamine activity in the brain. 
Via Stocktwits
News headline image
Axsome Therapeutics Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
2 Under-the-Radar Stocks to Buy Heading Into 2026 ↗
These drugmakers are poised to profit from their innovative engines. 
Via The Motley Fool
News headline image
Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth
As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Axsome (AXSM) Q3 2025 Earnings Call Transcript ↗
Axsome (AXSM) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pomerantz LLP and The Rosen Law Firm, P.A. Announce Proposed Class Action Settlement on Behalf of Purchasers of Axsome Therapeutics, Inc. Common Stock - AXSM
From Pomerantz LLP
Via GlobeNewswire
News headline image
2 Monster Stocks in the Making ↗
There might still be time to get in on the ground floor. 
Via The Motley Fool
News headline image
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Inc (NASDAQ:AXSM) Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Axsome Therapeutics Q3 2025 results: Revenue beat expectations with strong product sales, but the company reported a wider-than-expected loss. 
Via Chartmill
News headline image
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Axsome Therapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years ↗
Both should have significant catalysts by the end of the decade. 
Via The Motley Fool
News headline image
Pharma Tariffs Back In Spotlight On New Trump Threat ↗
President Donald Trump threatened 100% tariffs on some drug imports. 
Via Investor's Business Daily
Topics ETFs Government World Trade
News headline image
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apnea 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Prediction: These 2 Biotech Stocks Could Double in the Next 5 Years ↗
Both companies have made significant progress in recent years. 
Via The Motley Fool
News headline image
A Glimpse Into The Expert Outlook On Axsome Therapeutics Through 8 Analysts ↗
 
Via Benzinga
News headline image
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 Years ↗
FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025. 
Via Benzinga
News headline image
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.